[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633557":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":30,"responsibleParty":51,"collaborators":11,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Tang-Du Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Propranolol administered via intravenous pump for successive 7 days.","EXPERIMENTAL",null,[13],"Drug: Intravenous Pump-Delivered Propranolol",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Intravenous Pump-Delivered Propranolol","During the dose escalation phase, the proposed five dose levels of intravenous pump infusion of propranolol hydrochloride injection are as follows:\n\n* 0.01 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night;\n\n  * 0.02 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night;\n\n    * 0.03 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night; ④ 0.04 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night; ⑤ 0.05 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Yan Qu, M.D.","CONTACT","+86-18629074363","yanqu0123@icloud.com",{"name":27,"role":23,"phone":28,"phoneExt":11,"email":29},"Shunnan Ge, M.D.","+86-18165295569","gesn8561@163.com",[31],{"facility":32,"status":11,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Department of Neurosurgery , Tangdu Hospital, Fourth Military Medical University","Xi'an","Shaanxi","710038","China","CN",{"type":39,"coordinates":40},"Point",[41,42],108.92861,34.25833,{"lat":42,"lon":41},[45,46,48],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"name":22,"role":47,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":49,"role":50,"phone":11,"phoneExt":11,"email":11},"Shunnnan Ge, M.D.","SUB_INVESTIGATOR",{"type":52,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100633557","phase-1-an-open-label-dose-escalation-study-on-the-safety-tolerability-and-preliminary-efficacy-for-preventing-sap-by-intravenous-pump-delivered-propranolol-in-patients-with-ich-100633557",false,"NCT07528235","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing Stroke-Associated Pneumonia of Intravenous Pump-Delivered Propranolol in Patients With Intracerebral Hemorrhage","PROCHASE-DoE","Inclusion Criteria:\n\n* Patients aged \\> 18 and ≤ 80 years of age;\n* Can be treated with the study drug within 24 h of symptom onset;\n* No fever or infection was observed upon admission;\n* NIHSS score ≥10;\n* Supratentorial parenchymal haematoma (≥10 mL);\n* GCS score ≥ 6;\n* Patients or their family members sign informed consent forms.\n\nExclusion Criteria:\n\n* Infections within the last 4 weeks;\n* Use of antibiotics within the last 2 weeks;\n* Known pre-ICH dysphagia;\n* Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes;\n* Previous disability with pre-ICH mRS score ≥ 2;\n* Brainstem hemorrhage;\n* Life expectancy less than 14 days;\n* Death appeared imminent;\n* Pregnancy or within 30 d of delivery;\n* Previous use (within 1 month) of β-blockers or reserpine;\n* Bronchial asthma or COPD;\n* Cardiogenic shock;\n* Degree II-III atrioventricular blocks;\n* Severe or acute heart failure;\n* Heart rate \\\u003C 65 beats\u002Fmin;\n* Known to be allergic to propranolol;\n* Severe liver or renal insufficiency;\n* History of malignant tumors;\n* Currently participating in other interventional clinical trials;\n* Currently, immunosuppressants and immunotherapies are being administered.","ALL","10 Years","80 Years",{"count":65,"type":66},30,"ESTIMATED","INTERVENTIONAL",[69],"PHASE1","This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.",[72,73],"Intracerebral Hemorrhage","Stroke-Associated Pneumonia (SAP)",[75,72,76,77],"Propranolol","Stroke-Associated Pneumonia","Dose-Escalation Study","NOT_YET_RECRUITING","2026-04-07",{"date":81,"type":82},"2026-04-14","ACTUAL",{"date":84,"type":66},"2026-05-01",{"date":86,"type":66},"2026-11-01",{"name":5,"class":6},1]